Biora's Principal Product Emdogain Gained Recognition At Specialist-Conference In The United States.

MALMO, Sweden--(BUSINESS WIRE)--Oct. 1, 1999--

Biora AB (Nasdaq: BIORY, SSE: BIOR) today announced that at this year's AAP conference (American Academy of Periodontology, the leading organization for periodontology), which ended on September 29, several American and European specialists presented their own positive clinical experiences and supporting data concerning Emdogain, Biora's principal product, relating to the surgical application of the product. The conference was arranged by AAP, in San Antonio, Texas, and was attended by approximately 6,000 periodontists and dentists from all over the world.

Among the speakers was Dr David Cochran, Professor and Chair, Department of Periodontics, University of Texas, Health Science Center, San Antonio Texas, who described his new research on Emdogain's mechanism of action. The study provides a better understanding of extracellular matrix (Emdogain) interaction on a cellular level, further strengthening earlier research findings that Biora presented at the International Association for Dental Research in Vancouver, March, 1999. Another interesting study was presented by Dr Stuart Froum, Clinical Professor of Periodontics, Clinical Professor of Implant Dentistry and Director of Research, Department of Implant Dentistry, New York University. The positive results of this study showed how Emdogain, relating to the surgical application of the product, regenerated supporting tissues, including new bone, over a twelve-month period.

"This is now the third time we have participated in the annual meeting for periodontists in the United States, and each year Biora and our principal product, Emdogain, has attracted more attention," said Tomas Hammargren, Biora's CEO. "We believe that there is a growing acceptance of Emdogain in the United States, based on the fact that more than half a dozen periodontal opinion-leaders presented positive results from their clinical experiences with the product."

Biora develops, manufactures and sells products for the treatment of periodontal disease and for use in oral surgery. Using its proprietary technology and expertise, Biora aims to become a world leader in biology-based products for specialized dental therapy. Biora's American Depository Shares are listed on the Nasdaq National Market in the US and Biora's ordinary shares are listed on the "O-list" of the Stockholm Stock Exchange in Sweden.

This press release may contain certain forward- looking statements that relate to future events or future business and financial performance. Such statements can only be predictions and the actual events or results may differ from those discussed. The Company cautions that these statements are subject to important factors that could cause actual results to differ materially from those expressed or implied in such forward looking statements and are more fully discussed in periodic reports filed with Securities and Exchange Commission.